Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
31.98
+2.60 (8.85%)
Apr 17, 2026, 4:08 PM HKT

HKG:3378 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Other Revenue
16.622.22.54
16.622.22.54
Revenue Growth (YoY)
655.62%-13.39%-
Gross Profit
16.622.22.54
Selling, General & Admin
58.0646.1917.22
Research & Development
89.3674.7246.66
Operating Expenses
147.42120.9163.88
Operating Income
-130.81-118.71-61.34
Interest Expense
-11.62-9.38-2.28
Interest & Investment Income
-2.924.13
Currency Exchange Gain (Loss)
-0.94-
Other Non Operating Income (Expenses)
-2.61--
EBT Excluding Unusual Items
-145.04-124.23-59.5
Gain (Loss) on Sale of Investments
-1.41-33.92
Pretax Income
-145.04-122.82-93.42
Income Tax Expense
-13.54-5.9-8.26
Earnings From Continuing Operations
-131.49-116.92-85.16
Minority Interest in Earnings
0.491.099.1
Net Income
-131.01-115.83-76.06
Net Income to Common
-131.01-115.83-76.06
Shares Outstanding (Basic)
118117
Shares Outstanding (Diluted)
118117
Shares Change (YoY)
979.68%49.83%-
EPS (Basic)
-1.11-10.60-10.42
EPS (Diluted)
-1.11-10.60-10.42
Free Cash Flow
--111.1-56.23
Free Cash Flow Per Share
--10.16-7.71
Gross Margin
100.00%100.00%100.00%
Operating Margin
-787.24%-5398.55%-2416.07%
Profit Margin
-788.44%-5267.39%-2995.51%
Free Cash Flow Margin
--5052.48%-2214.49%
EBITDA
-128.79-116.7-60.83
D&A For EBITDA
2.022.020.52
EBIT
-130.81-118.71-61.34
Source: S&P Global Market Intelligence. Standard template. Financial Sources.